Shots:
- The US FDA has approved Nucala as an add-on treatment for inadequately controlled COPD & eosinophilic phenotype based on the P-III (MATINEE & METREX) trial; EMA & NMPA’s submissions are under review
- MATINEE assessed Nucala (n=403; 100mg, SC, Q4W) vs PBO (n=401) in COPD pts (n=804) with type 2 inflammation while METREX evaluated it vs PBO in 836 pts across eosinophilic & non-eosinophilic phenotype group for 52wks.
- Both trials showed reduced annualized mod. or sev. exacerbation rates in the eosinophilic phenotype with added triple inhaled therapy while in MATINEE, Nucala also lowered COPD exacerbations requiring ED visits &/or hospitalization (2EP); MATINEE & METREX data were published in The NEJM
Ref: GSK| Image: GSK| Press Release
Related News:- GSK Receives the MHLW’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
